Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation for Postoperative Headache Following Stent-Assisted Coiling of Unruptured Intracranial Aneurysms
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07479082, who can take part
Where in China
- Capital Medical University Affiliated Beijing Tiantan HospitalBeijing, ChinaContact: Qingyuan Liu, M.D.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Tiantan Hospital
- Trial code
- NCT07479082
- Record updated
- 18 March 2026
- Original description
The goal of this clinical trial is to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in reducing postoperative headache among adults undergoing stent-assisted coiling for unruptured intracranial aneurysms (UIAs). The study will include male and female participants aged 18 to 80 years who are scheduled for endovascular treatment of UIAs with stent-assisted coiling or flow diverter devices.Read full original descriptionShow less
The goal of this clinical trial is to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) in reducing postoperative headache among adults undergoing stent-assisted coiling for unruptured intracranial aneurysms (UIAs). The study will include male and female participants aged 18 to 80 years who are scheduled for endovascular treatment of UIAs with stent-assisted coiling or flow diverter devices.
The main questions it aims to answer are:
* Can taVNS reduce the incidence of headache within 90 days after stent-assisted embolization of UIAs? * Is taVNS safe and well-tolerated in this patient population? Researchers will compare patients receiving active taVNS to those receiving sham stimulation to determine if taVNS leads to fewer postoperative headaches and reduced need for analgesic medications.
Participants will:
* Wear a taVNS device on the left earlobe (active group) or cymba conchae (sham group) starting 1 day before the procedure * Receive 30-minute stimulation sessions, twice daily, until postoperative day 5 * Undergo follow-up assessments of headache occurrence, pain intensity, analgesic use, and any adverse events through day 90 after the procedure
Inclusion: Age 18-80 years; Diagnosed with unruptured intracranial aneurysm confirmed by imaging; Planned to undergo stent-assisted coiling or flow diverter embolization; Signed informed consent.
Exclusion: Previous vagotomy, migraine surgery, or implanted neurostimulators; Other concurrent electronic/implantable devices (e.g., pacemakers, neurostimulators); History of SAH, ICH, brain tumor, major trauma, substance abuse, syncope, or seizures; Primary headache disorders (e.g., migraine, cluster headache, trigeminal neuralgia) not attributed to UIA; Clinically significant hypotension, congenital heart disease, severe arrhythmia, unstable angina, or recent MI; Inability to follow up due to severe psychiatric disorder or refusal; Recurrent/traumatic/infectious/myxomatous aneurysms; Skin lesions at taVNS placement site; Pregnant or lactating; Participation in other trials.